Stock price when the opinion was issued
Worth taking a good, hard look at. Phenomenal yield, and he likes yield. Chart is starting to form a bit of a bottom. Low PE. Has things in the pipeline that the market's not paying for. If you're a longer-term investor, well worth sitting on it and getting rewarded while you wait for an upside pop from the drugs coming through as hoped.
He's looking at it closely.
We reiterate PFE as a TOP PICK. With a ROE of 36% and trading at 7x earnings this is good value here. The company expects to hear soon if its RSV vaccine will get approval as one of the first available for people over 60 years of age. Cash reserves continue growing while the company retires debt. It pays a nice dividend, backed by a payout ratio un 30% of cash flow. We continue to recommend a stop-loss at $35, looking to achieve $52.50 - upside potential over 28%. Yield 3.9%
(Analysts’ price target is $52.52)